^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Viracept (nelfinavir)

    i
    Other names: AG 1343, LY 312857, AG-1343, LY-312857, AG1343, LY312857
    Company:
    Roche, ViiV Healthcare
    Drug class:
    AKT inhibitor, Protease inhibitor
    Related drugs:
    1m
    NELCER: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (clinicaltrials.gov)
    P3, N=348, Active, not recruiting, Tata Memorial Hospital | Trial completion date: Sep 2025 --> Jan 2026
    Trial completion date
    |
    cisplatin • Viracept (nelfinavir) • ondansetron intravenous
    1m
    Darunavir analog precursors target mitochondrial metabolism in multiple myeloma and CLL. (PubMed, Cancer Cell Int)
    BupM-NH2, and particularly BnpM-NH2, showed enhanced cytotoxicity against MM, CLL, and NDMM cells compared to PBMCs by inducing apoptosis through autophagy and mitochondrial respiration inhibition. While the cytotoxic effect in RRMM is less pronounced and nonsignificant, BupM-NH2 and BnpM-NH2 induces stress in respiratory chain and mitochondria, which may re-sensitize resistant tumor cells to treatments. Therefore these compounds may hold promise as novel therapeutic agents for MM and CLL treatment.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    Venclexta (venetoclax) • bortezomib • Viracept (nelfinavir)
    1m
    Autophagy Maintenance (AUTOMAIN) (clinicaltrials.gov)
    P2, N=38, Recruiting, Medical University of South Carolina | Not yet recruiting --> Recruiting | N=20 --> 38 | Trial completion date: Dec 2027 --> Jun 2029 | Trial primary completion date: Dec 2026 --> Jun 2028
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • hydroxychloroquine • Viracept (nelfinavir)
    2ms
    Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow (clinicaltrials.gov)
    P1/2, N=10, Recruiting, University of California, Irvine
    New P1/2 trial
    |
    Viracept (nelfinavir)
    3ms
    Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=25, Recruiting, M.D. Anderson Cancer Center | N=18 --> 25
    Enrollment change
    |
    cisplatin • Viracept (nelfinavir)
    4ms
    COAST Therapy in Advanced Solid Tumors and Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Medical University of South Carolina | Trial completion date: Oct 2026 --> May 2027 | Trial primary completion date: Oct 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    dasatinib • sirolimus • metformin • hydroxychloroquine • Viracept (nelfinavir)
    4ms
    Autophagy Maintenance (AUTOMAIN) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Medical University of South Carolina | Initiation date: Sep 2025 --> Jan 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • hydroxychloroquine • Viracept (nelfinavir)
    4ms
    Nelfinavir triggers ferroptosis by inducing ER stress mediated downregulation of GPX4/GSH system, upregulation of NRF2/HO-1 axis, and mitochondrial impairment in hepatocellular carcinoma cells. (PubMed, Cell Death Discov)
    In a mouse model of HCC xenografts, nelfinavir treatment significantly suppressed tumor growth, and this effect was more pronounced when nelfinavir and sorafenib were administered together. Collectively, we demonstrate that nelfinavir can induce ferroptosis in an ER stress dependent manner, thereby identifying a new inducer of ferroptosis that can potentially be repurposed to treat HCC.
    Journal
    |
    HMOX1 (Heme Oxygenase 1) • GPX4 (Glutathione Peroxidase 4)
    |
    sorafenib • Viracept (nelfinavir)
    6ms
    NELCER: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (clinicaltrials.gov)
    P3, N=348, Active, not recruiting, Tata Memorial Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • Viracept (nelfinavir) • ondansetron intravenous
    7ms
    Autophagy Maintenance (AUTOMAIN) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Medical University of South Carolina | Initiation date: Jun 2025 --> Sep 2025
    Trial initiation date
    |
    Avastin (bevacizumab) • hydroxychloroquine • Viracept (nelfinavir)
    8ms
    Machine learning-based identification of exosome-related biomarkers and drugs prediction in nasopharyngeal carcinoma. (PubMed, Discov Oncol)
    This study identifies five exosome-related key genes, utilizing machine learning approaches to develop a diagnostic model and uncover potential drug targets for NPC. These findings offer novel perspectives for both the diagnosis and therapeutic development of NPC.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CCL2 (Chemokine (C-C motif) ligand 2) • LGALS3 (Galectin 3) • LGALS3BP (Lectin galactoside-binding soluble 3-binding protein)
    |
    Viracept (nelfinavir)
    9ms
    Autophagy Maintenance (AUTOMAIN) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Medical University of South Carolina
    New P2 trial
    |
    Avastin (bevacizumab) • hydroxychloroquine • Viracept (nelfinavir)